AI
CTKB icon

Acuitas Investments’s Cytek Biosciences CTKB Stock Holding History

Acuitas Investments’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-331,219
Closed -$1.33M – 61
2025
Q1 		$1.33M Buy
+331,219
New +$1.72M 1.13% 36

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Acuitas Investments's CTKB Position: Q2 2025 in Review

Acuitas Investments sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 331,219 shares — an estimated $1.33M sold.

Acuitas Investments first reported a position in CTKB in Q1 2025 and held it in 1 quarter. The position peaked at $1.33M in Q1 2025. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • Acuitas Investments reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • Acuitas Investments sold 331,219 Cytek Biosciences shares in Q2 2025, an estimated $1.33M.
  • Acuitas Investments first reported a position in Cytek Biosciences in Q1 2025 and held it in 1 quarter.
  • Acuitas Investments's Cytek Biosciences position peaked at $1.33M in Q1 2025.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Acuitas Investments's 13F filing for Q2 2025, filed 31 Jul 2025.